Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Nomura Holdings Inc.

Key Points

• Nomura Holdings Inc. increased its stake in Jazz Pharmaceuticals PLC by 27.4% during the first quarter, acquiring an additional 2,195 shares and holding a value of approximately $1.27 million.
• Several hedge funds have changed their positions in Jazz Pharmaceuticals, with a high 89.14% of the company's stock now owned by institutional investors.
• Jazz Pharmaceuticals reported a quarterly earnings miss, posting a ($8.25) EPS, which was below analysts' expectations of ($5.61).

Nomura Holdings Inc. lifted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 27.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,217 shares of the specialty pharmaceutical company's stock after acquiring an additional 2,195 shares during the quarter. Nomura Holdings Inc.'s holdings in Jazz Pharmaceuticals were worth $1,268,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Hsbc Holdings PLC lifted its holdings in Jazz Pharmaceuticals by 26.7% during the 4th quarter. Hsbc Holdings PLC now owns 2,871 shares of the specialty pharmaceutical company's stock worth $354,000 after buying an additional 605 shares during the period. Northern Trust Corp grew its position in Jazz Pharmaceuticals by 18.9% during the fourth quarter. Northern Trust Corp now owns 521,196 shares of the specialty pharmaceutical company's stock valued at $64,185,000 after acquiring an additional 82,817 shares during the last quarter. AXA S.A. bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $4,747,000. Algert Global LLC purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth about $1,682,000. Finally, Captrust Financial Advisors boosted its holdings in Jazz Pharmaceuticals by 7.5% in the fourth quarter. Captrust Financial Advisors now owns 5,337 shares of the specialty pharmaceutical company's stock worth $657,000 after purchasing an additional 372 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on JAZZ. Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a research note on Thursday, August 28th. Zacks Research raised shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Finally, Morgan Stanley boosted their target price on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $178.67.

Insider Buying and Selling

In other news, Director Bruce C. Cozadd sold 6,000 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director owned 429,973 shares in the company, valued at $55,303,127.26. The trade was a 1.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Stock Up 0.0%

Shares of Jazz Pharmaceuticals stock traded up $0.04 during trading on Monday, hitting $129.54. 271,471 shares of the stock traded hands, compared to its average volume of 942,851. The stock has a market cap of $7.86 billion, a P/E ratio of -19.23, a PEG ratio of 8.03 and a beta of 0.24. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The company has a fifty day moving average price of $116.68 and a two-hundred day moving average price of $116.77.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.